EUVIMEDEUVIMED entdecken
Open Access

Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Akifumi Kuwano, Masayoshi Yada, Kosuke Tanaka, Yuta Koga, Shigehiro Nagasawa, Akihide Masumoto, Kenta Motomura

Cancer Diagnosis & Prognosis · 02.01.2024 · 4 (1) · 34-41

DOI: 10.21873/cdp.10282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 02.01.2024. Verfasst von Akifumi Kuwano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim: Atezolizumab in combination with bevacizumab is an approved systemic chemotherapy regimen for advanced hepatocellular carcinoma (HCC). However, immune checkpoint inhibitors (ICIs), such as atezolizumab, frequently lead to immune-related adverse events (irAEs). The identification of biomarkers that can predict the occurrence of irAEs is crucial for the optimal management of patients undergoing ICI treatment. Patients and Methods: Between October 2020 and June 2023, we conducted a study involving 69 patients with advanced HCC who received treatment with atezolizumab plus bevacizumab. We conducted an analysis of blood-based biomarkers to identify independent risk factors associated with irAEs. Results: In our study, 12 out of 69 patients (17.4%) experienced irAEs. Our investigation into blood-based biomarkers revealed that a neutrophil–to-lymphocyte ratio (NLR)

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinomaatezolizumab plus bevacizumabimmune-related adverse eventsneutrophil-to-lymphocyte ratio

Autor:innen und Institutionen

  • Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.

Zitieren

APA

Kuwano, A., Yada, M., Tanaka, K., Koga, Y., Nagasawa, S., Masumoto, A., & Motomura, K. (2024). Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Cancer Diagnosis & Prognosis, 4(1), 34-41. https://doi.org/10.21873/cdp.10282

Vancouver

Kuwano A, Yada M, Tanaka K, Koga Y, Nagasawa S, Masumoto A, et al. Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Cancer Diagnosis & Prognosis. 2024;4(1):34-41. doi:10.21873/cdp.10282

BibTeX
@article{Kuwano2024,
  author = {Kuwano, Akifumi and Yada, Masayoshi and Tanaka, Kosuke and Koga, Yuta and Nagasawa, Shigehiro and Masumoto, Akihide and Motomura, Kenta},
  title = {Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab},
  journal = {Cancer Diagnosis & Prognosis},
  year = {2024},
  volume = {4},
  number = {1},
  pages = {34--41},
  doi = {10.21873/cdp.10282}
}
Kostenlos starten →